Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Prompt Diagnostics $1 million to further the development of a portable PCR platform to detect multiple pathogenic bacteria targets and their antibiotic susceptibility which will help to guide treatment at the point-of-care. If successful, Prompt’s approach could enable more effective treatment management and promote antimicrobial stewardship to prevent the development and spread of multi-drug resistant gonorrhea globally, particularly in low-resource settings with remote or limited access to secondary healthcare facilities.
Read more about our work with CARB-X here.